CNBC Pro highlights the top performing stocks this week and analyzes whether the good times will continue.» Read More
NEW YORK— Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:. Health Net Inc., up $6.51 to $71.57. The managed health care services company is being bought by Medicaid coverage provider Centene Corp. for about $6.3 billion.
Pfizer Inc, the largest U.S. drugmaker, for example reported more than $234.2 million in research payments and another $53.3 million in general payments. John Diliberti, a pediatric geneticist from Illinois, collected nearly $447,000 from Pfizer in consulting fees last year, the biggest single payment to an individual doctor by the drugmaker.
Technology, one of the hottest areas in the six-year bull market has hit a standstill in 2015. Here are the stocks that could buck the trend.
*Criminal, civil charges filed in New Jersey. Attorney Paul Fishman in New Jersey said Steven Fishoff, 58, the president of Featherwood Capital Inc in Westlake Village, California, was charged with four counts of securities fraud and one count of conspiracy. Also charged with securities fraud and conspiracy were Fishoff's brother-in-law Steven Costantin, 54,...
New data provided to CNBC from eVestment shows the most popular stocks held by institutional funds.
Nine S&P 500 stocks, including Kroger and Hanesbrands, outperform the most widely owned stocks by Millenials, USA Today reports.
Some view skyrocketing biotech stocks as a bubble, but hedge funds are riding optimism in the sector to monster gains—for now.
As CEOs buy a record amount of stock with shareholder money, they're keeping their wallets in their pockets when it comes to buying shares on their own.
--Amgen in late 2012 bought Decode Genetics for $415 million in cash to gain access to a database of complete genetic sequences of 2,636 Icelanders. --In January 2014, Regeneron Pharmaceuticals Inc signed a deal with Geisinger Health System in Pennsylvania to sequence DNA from as many as 250,000 volunteers from Geisinger's pool of 3 million patients.
Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...
Some of the names on the move ahead of the open.
Traders are watching the iShares Nasdaq Biotechnology ETF for clues on whether a deeper stock market decline is on the horizon.
Crowded "long" trades unwinding
As biotech has boomed over the last few years, so has real estate in Kendall Square in Cambridge, Massachusetts.
More than half of the S&P 500 is projected to rise by 8 percent in 12 months, according to analysts. Here are the stocks that could rise the most.
George Scangos, Biogen CEO, discusses progress in clinical trials for Alzheimer's treatments, and the outlook for its multiple sclerosis Tecfidera drug.
Biotech is getting roughed up, after leading the market's gains this year.
Biotech, which has been a market leader all year, is weak, with both the market-cap weighted IBB and equal weighted XBI down roughly 4 percent each.
U.S. stocks closed higher on Friday, with the Nasdaq setting another record as investors cheered major earnings reports.
April 24- Slowing sales of Biogen Inc's key oral multiple sclerosis drug Tecfidera and a delay in a data readout for its keenly watched Alzheimer's drug sent the company's stock down as much as 8 percent on Friday. If Tecfidera's U.S. trajectory does not improve, Biogen's revenue growth may come in at the lower end of its previously issued forecast, Chief...